publication . Article . Other literature type . 2009

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease: A Randomized Controlled Trial

Green, Robert C.; Schneider, Lon S.; Amato, David A.; Beelen, Andrew P.; Wilcock, Gordon; Swabb, Edward A.; Zavitz, Kenton H.;
Open Access
  • Published: 16 Dec 2009 Journal: JAMA, volume 302, page 2,557 (issn: 0098-7484, Copyright policy)
  • Publisher: American Medical Association (AMA)
  • Country: United Kingdom
Abstract
CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was...
Subjects
free text keywords: General Medicine, Tarenflurbil, medicine.drug, medicine, Cognitive decline, Surgery, medicine.medical_specialty, Clinical trial, Cognitive disorder, medicine.disease, Randomized controlled trial, law.invention, law, Alzheimer's disease, Tolerability, business.industry, business, Placebo, Article
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2009

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease: A Randomized Controlled Trial

Green, Robert C.; Schneider, Lon S.; Amato, David A.; Beelen, Andrew P.; Wilcock, Gordon; Swabb, Edward A.; Zavitz, Kenton H.;